This website is intended for US healthcare audience only. If you are seeking global VELTASSA information, please click here.
VELTASSA® (patiromer) for oral suspension
Important Safety Information INDICATION
VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.
Full Prescribing Information Patient Site Patient Support Services

Vifor Pharma can help your patients access and afford VELTASSA

Affordability
Commercially insured patients* may pay as low as $0 for VELTASSA

$ 0

co-pay
per month
for up to
12 months

  • Instant savings at the pharmacy
  • No co-pay card or print coupon required
  • No patient registration

* Program is for commercially insured patients. Patients enrolled in a government health insurance program, such as Medicare Part D, Medicaid, TRICARE, or Veterans Health Administration, are not eligible; this is not an exhaustive list of excluded government health plans. Patients may pay as low as $0 for up to 12 months; after that, renewal is required. Patient is responsible for applicable taxes. Annual maximum limits may apply. Co-pay program is not insurance. No party may seek reimbursement for any part of the co-pay benefit received under this program. See full Terms and Conditions below.

Multiple pharmacy options to
fit your patients’ needs

Enjoy the freedom to prescribe
VELTASSA through different channels.

Retail Pharmacy

Retail Pharmacy

  • Patients’ access support may be limited
  • Patients pick up
    medication locally
Specialty pharmacy

Specialty pharmacy

  • Researches patients’ insurance coverage and provides prior authorization (PA) information
  • Ships medication to patients through the mail
VELTASSA Konnect

VELTASSA Konnect

  • Offers access support,
    trial supply, and ongoing support
  • Specialty pharmacy ships prescriptions directly to patients

VELTASSA Konnect may help patients
start and stay on therapy

Veltassa Konnect

Enroll your patients with the VELTASSA Konnect Enrollment Form

VELTASSA Konnect helps with:

Access support

Access support

Researches patients’ insurance coverage and provides information on PAs and appeals if needed. Case managers are available to answer questions

Trial supply

Trial supply

A free trial supply (up to 20 days) is available for patients upon healthcare professional request through the VELTASSA Start Program

Financial assistance

Financial assistance

Assesses need and potential eligibility for qualified patients

Delivery

Delivery

Specialty pharmacy ships prescriptions directly to patients

Ongoing support

Ongoing support

Stay-on-Track, an adherence program, offers patients ongoing support and lifestyle tips. Nurse advocates are available to answer patients’ questions


Use of the VELTASSA Konnect program is not a guarantee of payment or reimbursement. Coverage is subject to individual
insurance plans, which may vary.

The VELTASSA Start Program is not contingent on purchase. This is a one-time-only supply and may be subject to additional restrictions. There is no guarantee that VELTASSA will be approved by patients’ health plans.

VELTASSA Konnect does not provide medical advice. Patients should consult their HCP if they have any questions about their
health or treatment.

Access patient resources for your
office and patients

VISIT PATIENT SUPPORT SERVICES


VELTASSA Konnect Enrollment Form can help expedite access
to VELTASSA for your patients

DOWNLOAD FORM IN ENGLISH DOWNLOAD FORM IN SPANISH



Automated PA support with covermymeds®

Support covermymeds
covermymeds
  • Monitors and tracks
    progress of PAs
  • Reminds your office of any
    action needed to complete PAs
  • Notifies pharmacies if PAs
    are approved
  • Provides specific appeals
    process information to
    payers if PAs are denied

For PA assistance
and more information,
visit covermymeds.com.



$0 Co-pay Important Terms and Conditions

By participating in Vifor Pharma, Inc.’s (Vifor Pharma) Pay as Low as $0 Co-pay Program (“Co-pay Program”) for VELTASSA, the patient acknowledges that, at the time of usage, they meet the eligibility criteria and comply with the following terms and conditions.

The Co-pay Program is for commercially insured patients. Patients with prescription coverage through any type of federal or state government-funded program are not eligible (eg, Medicare, Medicaid, TRICARE, Veterans Administration [VA], Mi Salud).

The patient may pay as low as $0 per month for up to a 12-month period, and afterward renewal is required. Annual maximum limits may apply. The Co-pay Program for VELTASSA is not insurance. Vifor Pharma reserves the right to rescind, revoke, or amend this program without notice. The patient must use the Co-pay Program for a valid prescription of VELTASSA, and this cannot be combined with any other coupon, trial, savings card, free drug assistance, or other offer.

Patient must live in the United States (including the District of Columbia, Puerto Rico, and the US Virgin Islands). If the patient is enrolled in VELTASSA Konnect, patient is required to promptly inform VELTASSA Konnect of any change in insurance status during the course of enrollment.

The patient and participating pharmacy are each obligated to inform the insurance plan of any benefit received under the Co-pay Program as required and may not participate if the Co-pay Program conflicts with the plan’s policy. No party may seek reimbursement for any part of the benefit received by patient under the Co-pay Program. The patient is responsible for applicable taxes. Limit one per person; offer is non-transferable and void where prohibited by law or restricted.

Important Safety Information, including Boxed WARNING

Indication

VELTASSA is indicated for the treatment of hyperkalemia.
Limitation of Use: VELTASSA should not be used as an emergency treatment for life‑threatening hyperkalemia because of its delayed onset of action.


Important Safety Information

CONTRAINDICATIONS
  VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

 

WARNINGS AND PRECAUTIONS
  Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please click here for full Prescribing Information.



Indication

VELTASSA is indicated for the treatment of hyperkalemia. Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Important Safety Information

CONTRAINDICATIONS VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.
WARNINGS AND PRECAUTIONS
Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post‑operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies. Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels. MOST COMMON ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.